Cogent Biosciences (NASDAQ: COGT) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. The company generates no product revenue as of its 10-K filed 2026-02-17, operating entirely on capital raises and carrying convertible note obligations. Its lead asset is bezuclastinib (CGT9486), a selective KIT tyrosine kinase inhibitor targeting the KIT D816V mutation and other KIT exon 17 mutations, in development for Non-Advanced Systemic Mastocytosis (NonAdvSM), Advanced Systemic Mastocytosis (AdvSM), and advanced gastrointestinal stromal tumors (GIST). The FDA granted Breakthrough Therapy Designation for bezuclastinib in NonAdvSM in October 2025, and orphan drug designation has been granted by both the FDA and EMA for Mastocytosis. A first NDA was submitted in December 2025 for NonAdvSM, with a second NDA for AdvSM expected in the first half of 2026. Cogent licensed exclusive worldwide rights to bezuclastinib from Plexxikon Inc., a Daiichi Sankyo subsidiary. Earlier-stage pipeline assets include CGT4859 (FGFR2/3 inhibitor) in Phase 1, and preclinical JAK2 and KRAS programs.

Revenue model

Pre-revenue clinical-stage company. No product sales as of the 10-K filed 2026-02-17. Operations are funded through capital markets activity. The company carries convertible note obligations.

Products and services

Bezuclastinib (CGT9486): selective KIT D816V / KIT exon 17 tyrosine kinase inhibitor in NDA review for NonAdvSM and late-stage development for AdvSM and GIST. CGT4859: FGFR2/3 small molecule inhibitor in Phase 1. Preclinical programs targeting JAK2 and KRAS.

Customers and end markets

Target patient populations: Systemic Mastocytosis (NonAdvSM and AdvSM), advanced and metastatic GIST. Rare and orphan disease end markets. U.S. commercial launch of bezuclastinib for NonAdvSM targeted for second half of 2026, pending FDA approval.

Value-chain role

Drug developer. Relies on third-party contract manufacturers for API and drug product supply for bezuclastinib, with sole-source API supply. Conducts clinical trials through third-party CROs. Building internal commercial organization for planned U.S. launch.

Geographic exposure

Development activities and planned initial commercial launch in the United States. EMA orphan drug designation obtained, indicating European regulatory engagement. Bezuclastinib licensed on exclusive worldwide rights basis from Plexxikon Inc.

Competitors

avapritinib (Blueprint Medicines)

Source: SEC 10-K, filed 2026-02-17

Industry: Pharmaceutical Preparations Peers: Avidity Biosciences, Inc. CareDx Inc Crinetics Pharmaceuticals Inc Erasca Inc Forma Therapeutics Holdings, Inc. Keros Therapeutics Inc Morphic Holding, Inc. POINT Biopharma Global Inc. Regenxbio Inc